If you are taking biologic medications, you can still be considered for refractive lens exchange as long as your condition is stable and well managed. What matters in practice is disease control, not just the diagnosis, and we usually confirm this with your medical history and, where needed, input from your specialist before proceeding.
Biologics can influence healing and slightly increase infection risk, so your surgical plan needs to be tighter. We focus on optimising your eye surface beforehand, using appropriate anti-inflammatory and antibiotic cover, and monitoring you more closely after surgery to avoid avoidable complications.
The key is coordination rather than exclusion. We decide on your medication timing with your treating doctor and tailor the approach to your situation, so you can move forward safely with a clear, structured plan.
What Is RLE Surgery?
Refractive lens exchange (RLE) is a procedure where your natural lens is removed and replaced with an artificial intraocular lens to improve your vision. It follows the same surgical principles as cataract surgery, but instead of treating a cloudy lens, the goal here is to reduce your reliance on glasses or contact lenses. In practice, we use it when laser options are not suitable or when you want a more permanent correction.
During the procedure, your surgeon removes the natural lens through a small incision and inserts a customised implant. The type of lens we choose depends on your visual priorities, whether that’s clear distance vision, better near vision, or a balance across all ranges. The surgery itself is quick, highly controlled, and usually done under local anaesthesia, so you remain comfortable throughout.
Because we are working inside the eye, recovery needs to be managed properly. Most patients heal smoothly, but we still assess any factors that could affect this, including medications like biologics, before going ahead. When you plan it properly, RLE becomes a predictable and well-structured route to long-term visual correction.
What Are Biologic Medications?
Biologic medications are targeted therapies used to manage autoimmune and inflammatory conditions by acting on specific parts of your immune system. Instead of broadly suppressing immunity, they interrupt precise pathways that drive inflammation, which is why they are both effective and more nuanced to manage. In practice, they are often introduced when standard treatments are not giving you enough control.
You will commonly see them used for conditions such as rheumatoid arthritis, psoriasis, Crohn’s disease, and ankylosing spondylitis. These include treatments like monoclonal antibodies and cytokine inhibitors, which work by modifying immune signalling rather than shutting it down completely. The aim is to reduce ongoing inflammation, control symptoms, and prevent long-term tissue damage.
Because they alter how your immune system behaves, they can influence how your body responds to surgery. This does not make procedures like RLE unsafe, but it does mean we plan more carefully around healing, inflammation, and infection risk. When handled properly, it becomes a matter of coordination rather than a barrier to treatment.
How Biologics Affect the Immune System
Biologic therapies work by selectively dampening specific immune pathways rather than suppressing the entire system. This targeted action reduces inflammation effectively, but it can also slightly reduce how quickly your body responds to infections. In practice, the impact varies depending on the drug, its mechanism, and how long you have been on it.
When you look at surgery, your immune system is central to how well you heal. It regulates inflammation, supports tissue repair, and protects against bacteria entering the eye during and after the procedure. If that response is modified, healing may not follow the usual pattern, which is why we approach planning more carefully.
This does not mean your recovery will be poor or unpredictable. It simply means we monitor you more closely, adjust medications where appropriate, and take extra precautions to reduce risk. With the right preparation and follow-up, we can maintain both safety and strong visual outcomes.
Infection Risk and Surgical Considerations
When you’re undergoing surgery while on biologic therapy, infection risk becomes something you actively manage rather than passively assume is covered. Because your immune system is modulated, even small exposures can behave differently compared to someone not on these medications. That doesn’t mean procedures like RLE are unsafe, but it does mean your surgical plan needs to be tighter, more deliberate, and aligned across your care team.
- Immune response is partially suppressed: Biologics are designed to dampen specific immune pathways, which helps control underlying conditions but can slightly reduce your ability to respond quickly to infections. In a surgical setting, this means even minimal bacterial presence requires more structured prevention rather than relying on natural immune clearance.
- Sterile protocols significantly reduce risk: RLE is performed in a controlled surgical environment with strict aseptic techniques. Pre- and post-operative antibiotic drops are used to minimise bacterial load, which plays a critical role in offsetting any increased susceptibility linked to biologic therapy.
- Healing may require closer observation: While most patients heal predictably, biologics can subtly influence tissue repair and inflammatory response. This doesn’t usually delay recovery significantly, but it does mean your surgeon will monitor healing more closely to catch any early deviations.
- Medication timing may be adjusted: In some cases, your clinician may review the timing of biologic doses around surgery to reduce peak immunosuppression during healing. This is always individualised, balancing surgical safety with the need to keep your primary condition stable.
- Follow-up is more structured and proactive: You’re likely to have more frequent post-operative reviews, not because complications are expected, but because early detection is key. Prompt reporting of symptoms like redness, discomfort, or vision changes allows for quick intervention if needed.
With the right precautions, RLE remains a safe and well-controlled procedure even if you’re on biologic therapy. What makes the difference is coordination when your surgeon and prescribing specialist align your care, you reduce uncertainty and keep outcomes predictable.
Healing Response After RLE
Healing after RLE is usually straightforward, with most patients recovering over a few days to weeks. When you are on biologic medication, the overall process does not change dramatically, but the way your body handles inflammation and repair can be slightly different. In practice, this may mean your recovery timeline is a bit less predictable rather than significantly delayed.
You might notice mild inflammation lasting a little longer than expected, but this is typically well controlled with anti-inflammatory eye drops. We do not leave this to chance we review you more closely in the early stages and adjust treatment quickly if needed. The common mistake is assuming symptoms will settle on their own, when early intervention keeps everything on track.
The key point is that most patients on biologics still heal very well after RLE. The difference is in how we manage you, not in whether you can recover successfully. With closer monitoring and a proactive approach, we maintain both safety and strong visual outcomes without unnecessary concern.
Timing of Biologic Therapy Around Surgery
In some cases, we adjust the timing of your biologic therapy around RLE, but this is never a blanket rule. The decision comes down to your specific medication, how stable your condition is, and your individual risk profile. In practice, many patients can continue treatment, while others benefit from a short pause to reduce infection risk.
Where a pause is considered, we time it carefully rather than stopping treatment arbitrarily. Some biologics are held for one dosing cycle before and after surgery, while others do not require any interruption at all. This is always agreed jointly with your prescribing specialist, because maintaining control of your underlying condition is just as important as managing surgical risk.
The priority is balance, not caution for its own sake. Stopping biologics unnecessarily can trigger a flare, which creates more risk than it removes. When we coordinate properly and tailor the plan to you, we keep both your systemic condition and your surgical outcome on track.
Pre-Surgical Assessment and Planning
Before moving ahead with RLE, we carry out a detailed medical assessment to understand your full clinical picture. This is not a tick-box exercise we review your medications, how stable your autoimmune condition has been, and whether there have been any recent flare-ups. If anything is uncertain, we clarify it early so you are not going into surgery with avoidable risk.
Your eye assessment is just as thorough because this is where outcomes are won or lost. We measure the cornea precisely, examine the retina, and assess the tear film and ocular surface in detail. If there is any dryness, blepharitis, or low-grade inflammation, we treat and stabilise it before setting a surgery date rather than trying to manage it afterwards.
When biologics are part of the picture, planning becomes more deliberate, not more difficult. We align your medication timing, confirm stability, and build a clear peri-operative plan so nothing is left to assumption. From your perspective, it should feel structured and controlled, with every step designed to keep the procedure safe and predictable.
The Role of Your Specialist Team
RLE planning works best when your care is coordinated across the right people. In practice, your ophthalmologist leads the surgical side, while your GP and the specialist managing your biologic therapy provide input on your overall health and disease control. This joined-up approach reduces gaps in decision-making and keeps the process clinically sound.
Clear communication between your specialists is what keeps risk under control. We align medication timing, confirm that your condition is stable, and ensure there are no conflicting priorities between treatment and surgery. If anything needs adjusting, it is handled in advance rather than reactively after the procedure.
You are not expected to coordinate this yourself. Your team takes responsibility for structuring the plan, guiding each step, and keeping everything aligned. When this is done properly, it removes uncertainty and allows you to move forward with confidence rather than second-guessing the process.
Who Can Safely Proceed With RLE?
If you’re considering RLE while on biologic therapy, the decision isn’t based on the medication alone it comes down to how stable and controlled your underlying condition is at the time of surgery. In practice, we don’t look for “perfect” cases; we look for predictability. When your condition is well-managed and your treatment plan is stable, surgery becomes far more straightforward from both a risk and recovery perspective.
- Well-controlled disease is the strongest green light: If your autoimmune or inflammatory condition has been stable for a sustained period, with no recent flares or medication changes, you’re generally in a safer position to proceed. Stability tells us your immune system is predictable, which directly supports smoother healing.
- Active inflammation increases surgical risk: If you’re currently experiencing a flare or heightened inflammatory activity, surgery is usually deferred. This isn’t about exclusion it’s about timing the procedure so your body isn’t already under stress, which reduces the chance of complications and inconsistent healing.
- Consistency in medication matters: Being on a stable biologic regimen without recent dose adjustments helps your care team plan around your immune status. Sudden changes in treatment can introduce variability, which is something we try to avoid during the surgical window.
- Systemic health plays a supporting role: Factors like overall immune function, presence of infections, or additional medications (such as steroids) are all considered. These don’t automatically disqualify you, but they shape how cautiously your case is managed.
- Individual assessment overrides general rules: There’s no blanket approval or restriction for patients on biologics. Your suitability is determined through a personalised evaluation, often involving coordination between your ophthalmologist and the specialist managing your biologic therapy.
In real terms, eligibility is less about whether you can have RLE and more about when it’s safest to do so. When timing, disease control, and care coordination align, outcomes tend to be both safe and predictable.
Situations Where Extra Caution Is Needed
There are situations where we slow things down rather than push ahead. If you have recently started or changed your biologic therapy, your immune response may still be settling, and that introduces uncertainty around healing. The same applies if your autoimmune condition is not well controlled or if you have an active infection these are clear signals to pause and stabilise before considering surgery.
From an eye perspective, any active inflammation needs to be fully addressed first. Conditions such as uveitis increase the risk of post-operative flare-ups, so we only proceed once the eye has been quiet and stable for an appropriate period. Trying to operate too early in these cases is one of the most avoidable causes of complications.
This is about timing, not denial. Delaying surgery in the short term often leads to a much smoother and safer outcome later. When we optimise your condition and plan properly, we shift the procedure back into a predictable, controlled setting rather than taking unnecessary risks.
Post-Operative Care and Monitoring
After RLE, follow-up is not optional it is where we protect your result. If you are on biologic therapy, we usually see you a bit more frequently in the early phase, not because problems are expected, but because we do not leave healing to assumption. Early review allows us to pick up subtle signs of inflammation or infection and act before they become clinically significant.
Your post-operative regimen will include antibiotic and anti-inflammatory eye drops, and this is where discipline matters. Missing doses or stopping early is one of the most common reasons for avoidable setbacks. We tailor the duration and intensity based on how your eye is responding, so you need to follow the plan rather than self-adjusting along the way.
In most cases, recovery is smooth and uneventful. The difference is in how closely we observe and how quickly we respond if something shifts. With structured follow-up and proper adherence, we keep the entire process controlled, predictable, and aligned with a strong visual outcome.
Long-Term Outcomes With Biologic Therapy
Long-term outcomes after RLE are consistently strong, even if you are on biologic therapy. In practice, the visual result you achieve is driven far more by surgical accuracy and lens selection than by your medication. As long as your condition is stable and the eye is well prepared, biologics do not meaningfully limit what we can achieve.
What makes the difference is how well the plan is tailored to you. When we account for immune modulation, optimise the ocular surface, and coordinate your medication properly, your outcomes track very closely with patients who are not on biologics. The mistake is assuming extra risk translates into worse results in reality, it just requires tighter execution.
Sustained success comes down to precision and consistency. Accurate biometry, the right intraocular lens choice, and disciplined post-operative care all compound over time. When these elements are handled properly, you are not just achieving good vision early on you are maintaining stable, reliable results for the long term.
Common Patient Concerns
Many patients come in assuming that biologic therapy automatically makes surgery risky. In reality, that is an overestimation. There are additional considerations, but when we manage them properly, overall risk remains low and controlled. What usually drives anxiety is not the actual risk, but the lack of clarity around how it is handled.
Another frequent concern is whether you will need to stop your medication. In practice, many patients continue biologics without interruption, while others may pause briefly depending on the drug and clinical context. The key is that this decision is individualised and coordinated with your specialist, not applied as a blanket rule.
What settles most of these concerns is direct, structured communication. When you understand why decisions are made and how your care is being managed, uncertainty drops quickly. Confidence does not come from reassurance alone it comes from seeing a clear, well-planned process tailored to you.
Balancing Benefits and Risks
When you’re weighing up RLE while on biologic therapy, the real decision sits in how confidently we can predict your outcome not just the visual result, but the safety profile around it. You’re not choosing between “good” and “bad” options; you’re deciding whether the improvement in visual independence justifies the controlled, manageable risks in your specific clinical context. That balance only works when your baseline is stable and your surgical variables are tightly managed.
- Visual gain vs clinical predictability: RLE can significantly reduce your dependence on glasses, particularly if you’re dealing with presbyopia or high refractive error. But the value of that gain depends on how predictable your healing and inflammatory response will be, which is where biologic therapy becomes part of the equation.
- Risk is adjusted, not amplified blindly: Being on biologics doesn’t automatically create high risk it shifts how we manage it. Infection control, healing response, and follow-up protocols are all tightened, meaning the risk is actively mitigated rather than passively accepted.
- Quality of life improvements are often substantial: For the right candidate, RLE isn’t a marginal upgrade it can remove daily visual dependency and improve functional comfort. This becomes particularly relevant if your current correction is limiting your routine or affecting consistency in vision.
- Safety decisions are timing-driven: Even if you’re a good candidate overall, proceeding during a period of instability whether from your condition or medication adjustments undermines that balance. The same patient can be “high risk” one month and “well-controlled” the next.
- Surgeon-led, individualised planning is critical: Your ophthalmologist isn’t just assessing your eyes they’re integrating systemic health, medication timing, and risk tolerance into one plan. This is where generic advice stops and tailored decision-making begins.
In practice, the balance usually leans in your favour when your condition is stable and your care is well-coordinated. The priority isn’t to rush into surgery, but to enter it at the point where benefits are maximised and risks are already under control.
Advances in Surgical Safety
Modern RLE is not the same procedure it was a decade ago. We now operate through micro-incisions with far less tissue disruption, which directly reduces inflammation and speeds up recovery. Add to that more precise biometry and lens calculation, and you get outcomes that are not just safer, but far more predictable.
For patients on biologics, this shift matters. Less surgical trauma means your eye has less to recover from, which helps offset any subtle changes in healing response. At the same time, tighter sterilisation protocols and refined peri-operative care reduce infection risk to a very low level when executed properly.
What you are seeing now is a procedure that has been engineered around control and consistency. Ongoing improvements in technique, technology, and clinical protocols continue to narrow variability, even in more complex cases. When you combine that with proper planning, biologic therapy becomes a factor we manage not a barrier to achieving a safe, high-quality outcome.
How Different Biologic Drugs May Affect Surgery Differently
Not all biologic drugs behave the same way around surgery, and this is where we avoid generalisations. Different agents target different immune pathways, so their impact on inflammation, infection risk, and healing varies. In practice, anti-TNF therapies, interleukin inhibitors, and B-cell–targeting drugs each come with slightly different considerations, which is why we tailor the plan rather than applying a single protocol.
From a surgical outcome perspective, there is no evidence that biologics affect the long-term stability of the intraocular lens or the quality of your vision. Once healing is complete, your visual result is expected to be as stable and reliable as any other patient. The variation lies in the early post-operative phase, not in the long-term performance of the procedure.
What keeps everything on track is structured follow-up and coordination with your wider care team. We monitor your eye closely, ensure your underlying condition remains controlled, and adjust management if needed. When handled this way, biologic therapy becomes part of the planning process, not a limitation and long-term outcomes remain consistently strong.
Psychological Confidence Before Surgery
Deciding to go ahead with RLE while on biologic therapy can feel like a bigger step than it actually is. Most of the hesitation comes from uncertainty how your body will respond, whether healing will be different, and if the risk is higher than usual. These concerns are valid, but in practice, they are addressed through planning rather than left unresolved.
Confidence builds when you can see how each risk is being managed. Once you understand that your condition is being assessed properly, your medication is being coordinated, and your recovery is being closely monitored, the procedure stops feeling unpredictable. What initially feels like a complex situation becomes a structured, controlled process.
Your surgeon’s role goes beyond the technical side of the procedure. You should feel able to ask direct questions, challenge decisions if needed, and understand exactly what is being done and why. When communication is clear and transparent, confidence follows naturally and that has a real impact on how comfortable you feel going into surgery and throughout recovery.
FAQs:
1. Can I safely have RLE if I’m on biologic medication?
Yes, in most cases you can proceed safely if your underlying condition is stable and well controlled. The decision is based on predictability of healing and infection risk, not simply the presence of biologic therapy. With proper planning and coordination, outcomes remain highly reliable.
2. Do I need to stop my biologic treatment before surgery?
Not always. Some patients continue treatment without interruption, while others may pause for a dosing cycle depending on the specific drug and clinical context. This decision is always individualised and agreed with your prescribing specialist.
3. Does biologic therapy increase the risk of infection after RLE?
There is a slightly increased risk due to immune modulation, but this is actively managed. Strict sterile protocols, antibiotic drops, and close follow-up significantly reduce this risk, keeping it low and controlled.
4. Will my healing be slower because of biologics?
Healing is usually still smooth, but it may be slightly less predictable. Mild inflammation can last a bit longer in some cases, which is why closer monitoring and timely adjustments to treatment are important.
5. Is RLE more risky for people with autoimmune conditions?
Not inherently. The key factor is how well your condition is controlled. Active inflammation or recent flare-ups increase risk, while stable disease allows for safe and predictable surgery.
6. How do doctors decide if I’m a suitable candidate?
Suitability is based on a combination of factors: stability of your condition, consistency of medication, ocular health, and overall immune status. A personalised assessment determines the safest timing and approach.
7. What happens if my condition flares up before surgery?
Surgery is usually postponed until your condition is stable again. Proceeding during a flare increases the risk of complications, so timing is adjusted to ensure a controlled and predictable outcome.
8. Will I need more follow-up appointments after RLE?
Yes, typically you’ll have slightly more frequent early follow-ups. This allows your surgeon to detect and manage any subtle changes in healing or inflammation before they become significant.
9. Do biologics affect the long-term results of RLE?
No, they do not impact the long-term visual outcome or stability of the intraocular lens. Once healing is complete, results are comparable to patients not on biologic therapy.
10. How can I prepare for surgery while on biologics?
Focus on maintaining stability in your condition, following your treatment plan, and attending all pre-surgical assessments. Clear communication between your care team ensures your medication timing and surgical plan are fully aligned.
Final Thoughts: Moving Forward with Confidence
Choosing to undergo refractive lens exchange while on biologic therapy is not about eliminating risk entirely, it is about managing it intelligently. When your condition is stable, your medication plan is well coordinated, and your surgical pathway is clearly structured, RLE becomes a controlled and predictable procedure rather than a complex one.
What matters most is timing and communication. When your care team aligns your treatment, monitors your recovery closely, and tailors every step to your individual profile, the presence of biologic therapy becomes something we plan around, not something that holds you back. If you’re considering RLE surgery in London, you can get in touch with us at London Cataract Centre.
References:
- Imam, M.S. et al. (2024), A meta-analysis examining the effect of perioperative biologic disease-modifying anti-rheumatic medications on postoperative wound complications in various orthopedic surgeries, Journal of Clinical Medicine, 13(18), 5531. Available at: https://www.mdpi.com/2077-0383/13/18/5531
- Baker, J.F. and George, M.D. (2019), Prevention of infection in the perioperative setting in patients with rheumatic disease treated with immunosuppression, Current Rheumatology Reports, 21(5), p. 17. Available at: https://pubmed.ncbi.nlm.nih.gov/30847768/
- Dutta Majumder, P. and Kene, R.D. (2025), Intraocular infections following biologicals and Janus kinase inhibitors, Indian Journal of Ophthalmology, 73(8), pp. 1091–1094. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC12416598/
- Lightner, A.L. (2023), Surgery for inflammatory bowel disease in the era of biologics, Journal of Crohn’s and Colitis. Available at: https://www.sciencedirect.com/science/article/abs/pii/S1091255X23015901
- van Duren, B.H. et al. (2021), To stop or not to stop: what should we be doing with biologic DMARDs when patients undergo orthopaedic surgery? Rheumatology Advances in Practice, 5(3), rkab057. Available at: https://academic.oup.com/rheumap/article/5/3/rkab057/6375959